Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Disease Progression × Melphalan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 224 Lymphoma 113 Leukemia, Myeloid, Acute 89 Lymphoma, Non-Hodgkin 88 Neoplasms, Plasma Cell 82 Myelodysplastic Syndromes 82 Precursor Cell Lymphoblastic Leukemia-Lymphoma 81 Leukemia 74 Hodgkin Disease 70 Leukemia, Lymphocytic, Chronic, B-Cell 58 Lymphoma, Large B-Cell, Diffuse 51 Lymphoma, Mantle-Cell 46 Lymphoma, Follicular 46 Burkitt Lymphoma 39 Neuroblastoma 36 Lymphoma, Large-Cell, Immunoblastic 35 Recurrence 31 Lymphoma, B-Cell, Marginal Zone 31 Hematologic Neoplasms 28 Myeloproliferative Disorders 27 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 27 Immunoglobulin Light-chain Amyloidosis 27 Leukemia, Myeloid, Accelerated Phase 23 Leukemia, Myelomonocytic, Chronic 22 Leukemia, Myeloid, Chronic-Phase 22 Congenital Abnormalities 20 Melanoma 19 Primary Myelofibrosis 18 Dendritic Cell Sarcoma, Interdigitating 18 Waldenstrom Macroglobulinemia 17

Interventions

Lenalidomide 4 Dexamethasone 4 Cyclophosphamide 4 Bortezomib 4 Cisplatin 3 Carboplatin 3 pomalidomide 2 pembrolizumab 2 fludarabine 2 durvalumab 2 capivasertib 2 Radiosurgery 2 Paclitaxel 2 Nivolumab 2 Gemcitabine 2 Bevacizumab 2 Anthropogenic Effects 2 venetoclax 1 vandetanib 1 umbralisib 1 ublituximab 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tremelimumab 1 tivozanib 1 ricolinostat 1 pazopanib 1 niraparib 1 nilotinib 1 lutetium Lu 177 dotatate 1 liposomal doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02043847 2024-11-13

BMT-03

University of Illinois at Chicago

Phase 1 Completed

12 enrolled 12 charts

Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡